ReviewFrontiers in oncology2021

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer.

Mo Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.